Several studies have shown that compared with monotherapy, the combination therapy of TIM3 or LAG3 inhibitors with PD-1 blockade therapy can significantly enhance anti-tumor activity, and patients have good tolerance to the combination therapy [256–260]. Here, HAVCR2 is linked to neoplasm.